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El7262 TheCloning and Characterization of a New
Regulatory Gene from Human Fetal Heart: A
Candidate for tha Control of Myocardial
Differentiation and Growth
I.C. Huggon, P.Towner, G. Moscoso, F. Farzaneh. Guy’s Hospital, London,
UK, King’s College Medical School, London, UK
Degenerate oligonucleotide prlmerawere used in thepolymerase chain reac-
tion (PCR) to clone the gene encoding a new transcription factor, designated
human GATA-6,from human fetal heart.
The GATA-family of transcription factors isagroupof regulatory molecules
which bind to genomic DNA and influence the rate at which specific genes
are transcribed. In blood precursors, GATA-factors 1 & 2 thus determine the
expression of the complete set of genes responsible for the structural and
functional proteins which confer the characteristics of individual cell types.
There is increasing evidence, augmented by our own work, that different
GATAfactors fulfil similar roles in other tissues including heart.
Degenerate primers were designed to stretches of amino acid sequence
conserved within a subgroup of the GATA-familyand used in PCR to amplify
fragments of putative related factors expressed in developing human heart.
The template was complementary DNA prepared from messenger RNA
extracted from human fetal heart. From a 340 base-pair gene fragment
isolated in this way, the full length transcript of a novel gene was cloned using
cDNA libra~ screening and PCR based methods. This transcript consists of
3663 base-pairs of which 1350 code for a 449 amino acid protein. There is
close sequence homology to members of the GATA-family,most particularly
to Xenopus GATA-6 and rat GATA-GT2 but also to GATA-4 of human and
other species.
Northern blot analysis and in-situ hybridisation studies have demonstrated
a tissue-restricted pattern of expression of GATA-6 confined to heart and
derivatives of the developing gut. Recent work by others showing that the
closest relative, GATA4 is able to influence the expression of some cardiac
specific genes in mouse suppotis the hypothesis that human GATA-6 also
functions in the regulation of myocardial differentiation.
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El7263 Gena Transfer of a Human HypertrophicCardiomyopathy Mutation into Adult Cardiac
Myocytes Inducea Sarcomere Disarray and Impairs
Contractility
A.J. Marian, G. Zhao, Q.-t. Yu, H. Oral, Y. Seta, R. Roberts. Baylor College
of Medicine, Houston, Texas, USA
To study the mechanism by which mutations in sarcomeric proteins cause
hypertrophic cardiomyopathy (HCM), we expressed human cardiac troponin
T (cTnT) with Argg2Glnmutation, known to cause HCM in man, in adult car-
diac myooyte and studied their structure and contractility. A full length human
cTnT cDNA was cloned, and the Argg2Glnwas induced. The normal (N) and
mutant (M) cDNAs were inserted into adenoviruses through homologous
recombination 3’ to a CMV promoter. Expression of the constructs into full
length protein was confirmed by western blotting and immunocytochemistry
using an antibody that distinguished between human and feline cTnTs.Over
75% of non-transduced myocytes and those transduced with vector alone
or cTnT-N had maintained their rod shape. In contrast, 61% of cells trans-
duced with the cTnT-M were round shape. Dose titration showed a direct
relation between expression level of mutant cTnT and the number of round
cells. Immunocytochemistry confirmed expression of human cTnT in rod and
round shape cells. Sarcomere structure was normal in all rod shape cells
including those in the cTnT-M group. However, severe sarcomere disarray
was present in round shape cells. Fractional cell shortening was measured
in rod shape cardiac myocytes and was reduced in the cTnT-M group aa
compared to cTnT-N group (5.32 + 1.2 vs. 6.16 * 0.65, p = 0.042). Thus,
expression of a mutant cTnT, known to cause human HCM, alters cardiac
myocyte structure and contractility. These findings provide a mechanism by
which mutations in the sarcomeric proteins could induce HCM.
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n7264 Mutationa in a Novel Gene Produce the Holt-Oram
Syndrome and Cardiac Septation Defacta
C.T. Basson, D.R. Bachinsky, R. Lin, L. Holmes, T. Train, B. Renault,
R. Kucherlapati, J.G. Seidman, C.E. Seidman. Brigham and kVornenk
Hospital, Boston, MA, USA, Harvard Medical School, Boston, MA, USA
Tha Holt-Oram syndrome is an autosomal dominant disorder characterized
by atrial and ventricular septal defects in the setting of upper limb deformity.
We have previously used genetic linkage analysis to localize the Holt-Oram
syndrome.genetic defect to the long arm of human chromosome 12. We now
report the identification of the Holt-Oram syndrome gene. Esfabliahment of
new polymorphic shorl tandem repeat genetic markers permitted the refine-
ment of the Holt-Oram Ikwustoan approximately 1CMinterval that is included
within a single 860 kb yeaat artificial chromosome clone. PI bacteriophage
clones were used to create an independent genomic oontig of this intewal.
Genetic analysis permitted the demonstration of new flanking markers which
define a minimal physical interval for the Holt-Oram locus that is encom-
passed by 4 PI clones. No known candidate genes were encoded within
these clones. Therefore, all 4 PI clones were aubjected to exon trapping
to find new coding sequences within this interval. These studiea resulted in
the cloning of a novel gene which causes the constellation of cardiac and
limb deformity that comprises the Holt-Oram syndrome. In different families
affected by the Hoit-Oram syndrome, single base pair changes as well as
more complex rearrangements have been identified within this gene. These
mutations produce the Holt-Oram syndrome, each with odds greater than
1,000,000:1. In addition, these mutations are not present in a panel of more
than 100 normal chromosomes. Ongoing mutational, structural, and func-
tional analysis of the Holt-Oram syndrome gene will provide new insights into
regulation of human cardiac development as well as novel approaches to
congenital heart disease diagnosis and management.
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1726-51 lnitiatiOnofTranSX’iPtiOnbYlheAtrial Myosin~ight
Chain 2 Promoter Requires the Presence of the INR
cis Efement
P,A.Doevendans1, P. Ruiz-Lozano2, R, Bronsaerl, K.R. Chien2, M. van
Bilsen 1. I Dept. of Cardiology and Physiology, CARIM, Maastricht, The
Netherlands, 2 UCSD La Jolla CA, USA
The murine atrial myosin light chain 2 (MLC-2a) gene is an important molec-
ular marker for cardiac chamber specification in oardiogenesis. The murine
expression pattern of MLC-2a becomes restricted to atrial tissue from day 10
throughout the adult stage. Recently the regulatory sequence of this gene
was cloned. This study was performed to identify cis elements required for
atrial specific expression. Method: Transient transfecfions wereperformed
on rat neonatal atrial myocytes and COS cells using deletion fragments (size
3.0, 1.2,0.45 and 0.2 Kb) of the MLC-2a 5’ flanking region cloned into pXPl
vector. By sequence analysis a conserved INR site (CTCAGTCT/A) was
~dentifiedat position –3 to +5 from the transcription start site. Partial (0.2 Ml)
and complete (0.2 M2) INR site deletions were studied. The 636 ANF pro-
moter and CMV/@-galactosidase(gal) were used as controls. Ludgal ratios
from three experiments are shown.
ANF 0.2 0.2M1 0.2M2 0.4s -.2 3.0
Conclusions:1)Partial or complete deletion of the INR site blunts MLC-2a
promoter activiiy. 2) The 0.2 and 0.45 Kbfragments provide strong transcrip-
tional activity in atrial myooytes, but not in COS cells.
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1726-61 The Afri~anOri9i”of the Common Mutetion in
African Amarican Patients with Glycogen Storage
Diseaae Type II (GSD 11)
J. Becker, E. Adams, P. Plotz, N. Raben. Chi/dren’s iVationa/Medics/
Centec Washington, DC, USA, ARB, rVIAMS,N/H, Bethesda, MD, USA
Cardiorespiratory failure is a major cause of death in infants suffering from
an inherited deficiency of a Iysosomal enzyme, acid a-glucosidase. The
infantile form of GSD II is characterized by deposition of glyoogen in the
heart, liver, and skeletal muscle. The disease is genetically heterogeneous:
multiple defects identified in the gene affect the synthesis, glycosylation,
phospho~lation or proteolytic processing of the enzyme. Here, we describe
a genetic study of an infantile patient from IVOIYCoast who has two mutations
in the gene. An unusual feature of the maternally-inherited mutation (T2846A;
Va1949Asp)is its l~alization 11nt upstream from the stop codon. Expression
studies show that the mutation results in complete inactivation of the enzyme.
The paternally-inherited mutation is equally interesting. We have identified a
